WuXi Biologics (Cayman) Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
WXXWY Over the counter 8731 www.wuxibiologics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for WuXi Biologics (Cayman) Inc.

WuXi Biologics Hosts Third CRDMO Day in Japan, Accelerating Biopharma Innovation from IND to Commercialization - May 19th, 2026 11:44 pm
WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index - May 12th, 2026 9:33 pm
Assessing WuXi Biologics (SEHK:2269) Valuation After Recent Share Price Weakness - May 11th, 2026 2:11 am
WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access - Apr 29th, 2026 6:30 am
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival - Apr 24th, 2026 5:03 am
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics - Apr 23rd, 2026 12:14 am
WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year - Apr 16th, 2026 11:30 pm
WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing - Apr 14th, 2026 8:39 pm
Assessing WuXi Biologics (SEHK:2269) Valuation After Choppy Returns And An Undervalued Narrative - Apr 9th, 2026 9:13 am
WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year - Mar 29th, 2026 11:33 pm
WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture - Mar 25th, 2026 4:22 am
WuXi Biologics Reports Record 2025 Annual Results - Mar 24th, 2026 5:44 am
World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target - Mar 21st, 2026 7:30 pm
WuXi Biologics Awards Win And Earendil Deal Viewed Against Valuation - Mar 15th, 2026 11:04 pm
WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation - Mar 12th, 2026 9:09 pm
Earendil Labs and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Bispecific/Multispecific Antibodies and ADCs - Mar 12th, 2026 3:00 am
Continuous Manufacturing Market Trends and Global Forecasts, 2035 Featuring Key Players - AbbVie, Abzena, AGC Biologics, Boehringer Ingelheim, Corden Pharma, Glatt, Kaneka, Phlow, and Wuxi Biologics - Mar 2nd, 2026 2:09 am
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year - Mar 1st, 2026 8:21 pm
Vertex Autoimmune Deal With WuXi Adds New Angle To VRTX Valuation Story - Feb 14th, 2026 11:09 pm
Vertex Expands Autoimmune Pipeline As Investors Weigh Valuation And Growth Potential - Feb 13th, 2026 2:19 am